Mycophenolate Dosing for NSIP
For nonspecific interstitial pneumonia (NSIP), start mycophenolate mofetil at 500 mg orally twice daily and gradually increase to a therapeutic dose of 1,000–1,500 mg twice daily, or use mycophenolic acid starting at 360 mg twice daily and increasing to 720–1,080 mg twice daily 1.
Dosing Strategy
The 2023 ACR/CHEST guideline provides the authoritative dosing framework for mycophenolate in autoimmune-associated interstitial lung disease, which includes NSIP patterns 1:
- Mycophenolate mofetil: Begin at 500 mg PO twice daily, then titrate gradually to 1,000–1,500 mg twice daily
- Mycophenolic acid: Begin at 360 mg PO twice daily, then titrate to 720–1,080 mg twice daily
The gradual dose escalation approach minimizes gastrointestinal side effects while achieving therapeutic immunosuppression.
Evidence Supporting This Dosing
The EVER-ILD trial, a randomized controlled study in patients with NSIP pattern ILD, used mycophenolate mofetil 2 g daily (1,000 mg twice daily) as the standard backbone therapy 2. This study demonstrated that MMF stabilized or improved lung function in NSIP patients, with the combination of rituximab plus MMF showing superior outcomes compared to MMF alone (FVC improvement of +1.60% vs -2.01% decline at 6 months, p=0.0273).
Real-world data from SSc-ILD patients treated with MMF showed overall functional stabilization, with DLCO improvement at 6 months, particularly in patients with NSIP pattern who exhibited less radiologic progression compared to UIP pattern 3.
Monitoring Requirements
Once you initiate mycophenolate, implement this monitoring schedule 1:
- Baseline: CBC with differential and comprehensive metabolic panel
- During titration: CBC and CMP at 2–3 weeks after starting and 2–3 weeks after any dose increase
- Maintenance: CBC and CMP every 3 months once on stable dose
- Annual: Full body skin examination by dermatologist
Critical Safety Considerations
Black box warning for pregnancy – Mycophenolate is highly teratogenic. Verify negative pregnancy test before initiation and ensure reliable contraception 1.
Watch for marrow suppression and hepatotoxicity during treatment. The EVER-ILD trial reported infections in 9 patients receiving rituximab plus MMF, including viral infections, emphasizing the need for vigilance regarding infectious complications 2.
Practical Implementation
Most patients tolerate the target dose of 1,000–1,500 mg twice daily. In the real-world SSc-ILD cohort, MMF was generally well tolerated with treatment discontinuation due to adverse events in only 5% of patients 3. If gastrointestinal side effects occur during titration, slow the escalation or consider dividing doses differently, but aim for the therapeutic range of 2–3 grams total daily dose for optimal disease control.
The evidence consistently supports 2 grams daily (1,000 mg twice daily) as the standard therapeutic dose for NSIP, with some patients requiring up to 3 grams daily (1,500 mg twice daily) based on disease severity and tolerance.